1. Home
  2. BMEA vs TLYS Comparison

BMEA vs TLYS Comparison

Compare BMEA & TLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMEA
  • TLYS
  • Stock Information
  • Founded
  • BMEA 2017
  • TLYS 1982
  • Country
  • BMEA United States
  • TLYS United States
  • Employees
  • BMEA N/A
  • TLYS N/A
  • Industry
  • BMEA Biotechnology: Pharmaceutical Preparations
  • TLYS Clothing/Shoe/Accessory Stores
  • Sector
  • BMEA Health Care
  • TLYS Consumer Discretionary
  • Exchange
  • BMEA Nasdaq
  • TLYS Nasdaq
  • Market Cap
  • BMEA 65.8M
  • TLYS 53.7M
  • IPO Year
  • BMEA 2021
  • TLYS 2012
  • Fundamental
  • Price
  • BMEA $1.73
  • TLYS $1.15
  • Analyst Decision
  • BMEA Strong Buy
  • TLYS Hold
  • Analyst Count
  • BMEA 11
  • TLYS 2
  • Target Price
  • BMEA $27.60
  • TLYS $3.75
  • AVG Volume (30 Days)
  • BMEA 713.5K
  • TLYS 87.3K
  • Earning Date
  • BMEA 05-05-2025
  • TLYS 06-05-2025
  • Dividend Yield
  • BMEA N/A
  • TLYS N/A
  • EPS Growth
  • BMEA N/A
  • TLYS N/A
  • EPS
  • BMEA N/A
  • TLYS N/A
  • Revenue
  • BMEA N/A
  • TLYS $569,453,000.00
  • Revenue This Year
  • BMEA N/A
  • TLYS N/A
  • Revenue Next Year
  • BMEA N/A
  • TLYS $5.21
  • P/E Ratio
  • BMEA N/A
  • TLYS N/A
  • Revenue Growth
  • BMEA N/A
  • TLYS N/A
  • 52 Week Low
  • BMEA $1.53
  • TLYS $1.14
  • 52 Week High
  • BMEA $13.43
  • TLYS $6.28
  • Technical
  • Relative Strength Index (RSI)
  • BMEA 41.85
  • TLYS 21.40
  • Support Level
  • BMEA $1.61
  • TLYS $1.14
  • Resistance Level
  • BMEA $2.30
  • TLYS $1.86
  • Average True Range (ATR)
  • BMEA 0.20
  • TLYS 0.13
  • MACD
  • BMEA -0.00
  • TLYS 0.00
  • Stochastic Oscillator
  • BMEA 21.74
  • TLYS 1.39

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About TLYS Tilly's Inc.

Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.

Share on Social Networks: